Compass Financial Management LLC Purchases New Stake in Teva Pharmaceutical Industries Ltd. $TEVA

Key Points

• Compass Financial Management LLC acquired 32,254 Teva shares during the second quarter, valued at approximately $1.09 million. Institutional investors and hedge funds collectively own 54.05% of Teva’s stock.
• Analyst sentiment remains positive, with nine analysts rating Teva a Buy and one assigning a Hold rating. The stock has a Moderate Buy consensus and an average price target of $42.89, while UBS recently raised its target to $48.
• Teva received an upgrade to investment-grade status from S&P Global Ratings, reported positive Phase IIa results for its celiac-disease therapy TEV ’408, and is considering a bid for BioXcel Therapeutics assets. These developments are counterbalanced by insider selling, including an executive’s sale of 106,563 shares.

Compass Financial Management LLC acquired a new position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 32,254 shares of the company's stock, valued at approximately $1,093,000.

A number of other hedge funds have also recently added to or reduced their stakes in TEVA. Aster Capital Management DIFC Ltd acquired a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter worth $25,000. Cornerstone Planning Group LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 547.1% in the 1st quarter. Cornerstone Planning Group LLC now owns 893 shares of the company's stock valued at $27,000 after buying an additional 755 shares during the period. Allworth Financial LP boosted its holdings in shares of Teva Pharmaceutical Industries by 53.8% in the 4th quarter. Allworth Financial LP now owns 941 shares of the company's stock valued at $29,000 after buying an additional 329 shares during the period. EverSource Wealth Advisors LLC grew its position in shares of Teva Pharmaceutical Industries by 51.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company's stock valued at $32,000 after buying an additional 345 shares during the last quarter. Finally, Global Retirement Partners LLC grew its position in shares of Teva Pharmaceutical Industries by 27.3% during the 4th quarter. Global Retirement Partners LLC now owns 1,360 shares of the company's stock valued at $42,000 after buying an additional 292 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company's stock.

Analysts Set New Price Targets

TEVA has been the topic of a number of recent research reports. Piper Sandler raised their target price on shares of Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the stock an "overweight" rating in a report on Tuesday, July 28th. Wall Street Zen lowered Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a report on Sunday, July 12th. Weiss Ratings upgraded Teva Pharmaceutical Industries from a "hold (c-)" rating to a "hold (c)" rating in a research report on Friday, August 21st. UBS Group raised their price target on Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the stock a "buy" rating in a report on Friday. Finally, Barclays boosted their price objective on Teva Pharmaceutical Industries from $40.00 to $42.00 and gave the company an "overweight" rating in a research report on Wednesday, August 12th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $42.89.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE TEVA opened at $36.36 on Monday. Teva Pharmaceutical Industries Ltd. has a 12-month low of $18.21 and a 12-month high of $38.37. The company has a market cap of $42.37 billion, a PE ratio of 60.60, a P/E/G ratio of 4.53 and a beta of 0.87. The stock has a 50 day simple moving average of $34.64 and a 200-day simple moving average of $33.28. The company has a current ratio of 0.88, a quick ratio of 0.67 and a debt-to-equity ratio of 1.56.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its earnings results on Tuesday, June 30th. The company reported $0.02 EPS for the quarter. The firm had revenue of $4.14 billion for the quarter. Teva Pharmaceutical Industries had a return on equity of 32.64% and a net margin of 4.08%. On average, equities research analysts forecast that Teva Pharmaceutical Industries Ltd. will post 1.94 EPS for the current year.

Key Stories Impacting Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: S&P Global Ratings upgraded Teva’s long-term issuer rating to BBB- from BB+ with a stable outlook. Combined with recent Fitch and Moody’s upgrades, Teva now has investment-grade ratings from all major agencies, potentially lowering borrowing costs and improving flexibility to invest in growth. S&P Global Ratings upgrades Teva
• Positive Sentiment: UBS raised its price target on TEVA to $48 from $42 and maintained a Buy rating, citing potential upside from the company’s improved financial profile and growth strategy.
• Positive Sentiment: Teva reported positive Phase IIa results for its anti-IL-15 therapy TEV ’408 in celiac disease. The treatment met the study goal of preventing gluten-induced intestinal damage and showed a favorable safety profile, strengthening the late-stage pipeline. TEV ’408 celiac disease study
• Neutral Sentiment: Teva agreed to act as stalking-horse bidder for substantially all BioXcel Therapeutics assets in a Chapter 11 auction, offering up to $125 million in cash plus assumed liabilities. The deal could expand Teva’s at-home treatment opportunity, but the final purchase price and assets acquired remain uncertain. Teva-backed BioXcel bid
• Neutral Sentiment: Teva is advancing a plan to exchange its ordinary shares for American Depositary Shares on the NYSE, which could simplify trading and broaden access for U.S. investors, although the immediate earnings impact is limited. Teva NYSE listing update
• Negative Sentiment: Reported insider activity has been heavily weighted toward selling, with no insider purchases and 14 sales over the past six months. This may temper investor enthusiasm, though insider sales can reflect compensation or portfolio decisions rather than deteriorating fundamentals.

Insider Activity

In other news, EVP Eliyahu Kalif sold 106,563 shares of the firm's stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $34.10, for a total transaction of $3,633,798.30. Following the transaction, the executive vice president directly owned 65,621 shares of the company's stock, valued at approximately $2,237,676.10. This trade represents a 61.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.54% of the company's stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. NYSE: TEVA is an Israeli multinational pharmaceutical company and one of the world's largest manufacturers of generic medicines. The company's core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva's product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source